What Is T U D C Aand Its Scientific Therapeutic Significance

Published

Table of Contents

Tauroursodeoxycholic acid (TUDCA) emerges as a multifaceted bile acid derivative with profound implications in biomedical research and clinical therapy. Beyond its role in bile acid metabolism, TUDCA demonstrates neuroprotective, anti-apoptotic, and metabolic regulatory properties that distinguish it from conventional therapeutic agents. Its unique molecular structure enables interactions with critical cellular pathways, positioning it as a promising candidate for treating neurodegenerative disorders, metabolic diseases, and liver pathologies.

From its precise chemical composition—defined by a tailored molecular weight of 515.7 g/mol and distinct solubility profiles—to its mechanistic influence on endoplasmic reticulum stress and mitochondrial function, TUDCA bridges fundamental science and translational medicine. Clinical studies further underscore its safety and efficacy, particularly in modulating autophagy, calcium homeostasis, and inflammatory responses, while preclinical research explores its potential as a chemosensitizer in oncology. This synthesis of biochemical, biological, and therapeutic insights underscores TUDCA’s role as a pivotal compound in modern pharmacology.

what is tudca

Scientific Definition and Chemical Properties of TUDCA

Tauroursodeoxycholic acid (TUDCA), a bile acid derivative, plays a pivotal role in hepatoprotection and neuroprotection due to its unique chemical structure and biochemical properties. Unlike conventional bile acids, TUDCA exhibits enhanced solubility and stability, making it a subject of extensive research in pharmaceutical and clinical applications. Its molecular characteristics distinguish it from other bile acids such as ursodeoxycholic acid (UDCA) and cholic acid (CA), influencing its therapeutic potential and pharmacokinetic behavior.

The chemical and physical properties of TUDCA are fundamental to understanding its biological activity and formulation in drug development. Below is a detailed examination of its molecular identity, solubility, stability, synthesis, and comparative physical attributes against related bile acids.

Chemical Identity and Molecular Structure

TUDCA is a taurine-conjugated bile acid with the IUPAC name:
3α,7β-dihydroxy-5β-cholan-24-oic acid sodium salt (25R)-24-amino-12-oxo-3,7,12-trihydroxy-24,25-dinor-5β-cholan-24-oic acid sodium salt.

Its molecular formula is C₂₆H₄₅NO₇SNa, and the molecular weight is 537.68 g/mol (monoisotopic). The structure comprises:

  • A steroid nucleus (5β-cholanic core) with hydroxyl groups at positions 3α and 7β.
  • A taurine moiety (2-aminoethanesulfonic acid) conjugated via an amide bond at the C24 carboxyl group.
  • A sodium counterion for ionic stabilization in solution.

    • The SMILES notation for TUDCA is:

    CC1C[C@H]2[C@@H](C[C@H](O)C[C@@H](O)CC[C@H]1CC[C@H]2C(=O)NCCS(=O)(=O)[O-])C(=O)O.[Na+]

    This notation reflects its stereochemistry, particularly the 5β-hydrogen and 3α,7β-dihydroxylation, critical for its biological activity.

    Solubility and Stability Profiles

    TUDCA demonstrates amphiphilic properties, enabling solubility in both aqueous and organic solvents, though its solubility varies significantly based on pH and solvent polarity.

    Solubility Data (25°C, unless specified):

  • Water: Highly soluble (~50–100 mg/mL at neutral pH), attributed to the ionic sodium salt and polar hydroxyl/taurine groups. Solubility decreases at pH < 3 (protonation of carboxyl/taurine) and pH > 10 (deprotonation of hydroxyl groups).
  • Ethanol: Moderately soluble (~10–20 mg/mL), influenced by hydrogen bonding with hydroxyl groups.
  • DMSO: Soluble (~50–70 mg/mL), due to dipole-dipole interactions with the solvent.
  • Chloroform/Methanol (1:1): Slightly soluble (~5 mg/mL), reflecting limited hydrophobic interactions.
  • Oil-in-water emulsions: Forms micelles at critical micelle concentration (CMC) ≈ 2–5 mM, enhancing bioavailability in biological systems.

    • Stability Under Varying pH:
    TUDCA exhibits pH-dependent stability:

  • Acidic conditions (pH 1–3): Prone to epimerization (3α-OH to 3β-OH) and deconjugation (taurine cleavage), reducing efficacy.
  • Neutral to slightly alkaline (pH 6–9): Most stable, retaining structural integrity for >6 months at room temperature.
  • Strongly alkaline (pH > 10): Risk of oxidative degradation (e.g., hydroxyl group oxidation to ketones) and sodium hydroxide-induced hydrolysis.

    • Thermal Stability:

  • Melting point: 230–235°C (decomposition observed above 250°C).
  • Storage conditions: Stable for 2+ years at −20°C in solid form; light-sensitive in solution (degradation via UV-induced oxidation).

    • Synthesis of TUDCA

    TUDCA is synthesized via chemical conjugation of taurine to ursodeoxycholic acid (UDCA), followed by purification. The process involves five key steps:

    Step 1: Activation of UDCA

  • UDCA is dissolved in dichloromethane (DCM) and reacted with dicyclohexylcarbodiimide (DCC) or N,N′-diisopropylcarbodiimide (DIC) to form an acyl chloride intermediate.
  • Reaction conditions: 0°C → room temperature, 2 hours.
  • Purpose: Facilitates nucleophilic attack by taurine.

    • Step 2: Coupling with Taurine

  • Taurine (2-aminoethanesulfonic acid) is added in molar excess (1.2:1) with triethylamine (TEA) as a base.
  • Reaction conditions: 4°C → 25°C, 12–24 hours, under nitrogen atmosphere (to prevent oxidation).
  • Product: Tauroursodeoxycholic acid (TUDCA) intermediate (free acid form).

    • Step 3: Neutralization and Salt Formation

  • The intermediate is dissolved in methanol/water (1:1) and titrated with 1 M NaOH to pH 7.0–7.5.
  • Purpose: Converts TUDCA to its sodium salt, improving solubility.

    • Step 4: Purification

  • Recrystallization: Precipitation from ethanol/water (3:1) at −20°C, followed by filtration.
  • Chromatography: Optional reverse-phase HPLC for high-purity applications (e.g., pharmaceutical-grade TUDCA).

    • Step 5: Drying and Storage

  • Lyophilization or vacuum drying at 40°C to remove residual solvents.
  • Final yield: 60–75% (theoretical), with >98% purity (HPLC analysis).

    • Key Reactants and Catalysts:

    Reactant/CatalystRoleQuantity (per 1 mmol UDCA)
    UDCAStarting bile acid1 mmol
    DCC/DICCoupling agent1.1 mmol
    TaurineConjugation partner1.2 mmol
    TEABase (neutralizes HCl byproduct)1.5 mmol
    NaOH (1 M)NeutralizationStoichiometric
    DCM/MethanolSolvents50 mL total
    Challenges in Synthesis:
  • Epimerization risk: Requires low-temperature conditions to preserve 3α-OH stereochemistry.
  • Side reactions: Dehydration (loss of 7β-OH) or taurine dimerization (if excess taurine is not controlled).
  • Scalability: Industrial synthesis often employs continuous-flow reactors to optimize yield.
    • The following table contrasts TUDCA with ursodeoxycholic acid (UDCA) and cholic acid (CA), highlighting differences in physical properties, solubility, and stability that influence their pharmacological profiles.
    Property TUDCA (Sodium Salt) UDCA (Free Acid) CA (Sodium Salt)
    Molecular Formula C₂₆H₄₅NO₇SNa C₂₄H₄₂O₄ C₂₄H₄₀O₅Na
    Molecular Weight (g/mol) 537.68 392.57 430.56
    Melting Point (°C) 230–235 (decomp.)

    Biological Roles and Mechanisms of TUDCA in the Body

    Tauroursodeoxycholic acid (TUDCA) exerts multifaceted biological effects through its interactions with bile acid signaling pathways, modulation of cellular stress responses, and neuroprotective mechanisms. Its ability to regulate endoplasmic reticulum (ER) homeostasis, mitigate oxidative damage, and influence mitochondrial function positions it as a key modulator of metabolic and neurodegenerative processes. Understanding these mechanisms elucidates its therapeutic potential in diseases characterized by ER stress, inflammation, and neuronal dysfunction.

    Interactions with Bile Acid Receptors and Cellular Pathways

    TUDCA primarily functions as a non-toxic bile acid that interacts with nuclear and membrane-bound receptors, including the farnesoid X receptor (FXR) and the Takeda G-protein-coupled receptor 5 (TGR5). Unlike endogenous bile acids, TUDCA exhibits low affinity for FXR but remains effective in modulating bile acid synthesis and transport via indirect pathways. Its interaction with TGR5—a receptor predominantly expressed in the liver, adipose tissue, and immune cells—triggers cAMP-dependent signaling, promoting anti-inflammatory and metabolic benefits.

    Key pathways influenced by TUDCA include:

  • FXR-mediated suppression of bile acid synthesis: TUDCA reduces hepatic expression of CYP7A1 and CYP8B1, enzymes critical for bile acid production, thereby alleviating bile acid-induced toxicity.
  • TGR5 activation and metabolic regulation: TUDCA enhances glucose uptake in skeletal muscle and lipid metabolism by activating TGR5, which increases intracellular cAMP levels and activates PKA (protein kinase A) signaling.
  • Inhibition of NF-κB and NLRP3 inflammasome: TUDCA suppresses pro-inflammatory cytokines (e.g., IL-1β, TNF-α) by blocking NF-κB activation and reducing NLRP3 inflammasome assembly, a mechanism relevant to metabolic syndrome and neuroinflammation.
    • TUDCA’s receptor-independent effects, such as membrane stabilization and mitochondrial protection, further distinguish its mechanisms from traditional bile acids.

    Modulation of Endoplasmic Reticulum Stress and Key Stress Proteins

    The endoplasmic reticulum (ER) stress response, mediated by the unfolded protein response (UPR), is a primary target of TUDCA. Under conditions of ER stress (e.g., oxidative damage, protein misfolding), three key sensors—PERK (PKR-like ER kinase), IRE1 (inositol-requiring enzyme 1), and ATF6 (activating transcription factor 6)—initiate adaptive or apoptotic pathways. TUDCA attenuates ER stress through multiple mechanisms:

    1. Suppression of PERK-mediated apoptosis:
    TUDCA reduces eIF2α phosphorylation, decreasing ATF4/CHOP expression, which otherwise promotes pro-apoptotic signaling. This effect is particularly relevant in neurodegenerative diseases, where chronic ER stress contributes to neuronal death.

    2. Inhibition of IRE1-JNK signaling:
    TUDCA blocks IRE1-mediated splicing of XBP1 and suppresses JNK (c-Jun N-terminal kinase) activation, preventing downstream apoptosis and inflammation. This pathway is critical in liver injury and metabolic disorders.

    3. ATF6-dependent restoration of ER homeostasis:
    TUDCA enhances ATF6α activation, promoting transcription of ER chaperones (e.g., BiP/GRP78, PDI) that restore protein-folding capacity. This mechanism is observed in diabetic nephropathy and neurodegenerative models.

    TUDCA’s ability to shift the UPR from pro-apoptotic to pro-survival pathways underlies its protective effects in conditions ranging from Alzheimer’s disease to non-alcoholic fatty liver disease (NAFLD).

    Neuroprotective Mechanisms: Flowchart of TUDCA’s Role in Mitochondrial Function and Oxidative Stress

    The following flowchart outlines TUDCA’s neuroprotective actions, emphasizing its mitochondrial and antioxidant effects:
    • Reduction of ER Stress:
      • Inhibits PERK/IRE1/ATF6 hyperactivation, reducing CHOP and caspase-12 expression.
      • Restores calcium homeostasis in the ER, preventing mitochondrial calcium overload.
    • Mitochondrial Protection:
      • Enhances mitochondrial membrane potential (Δψm) by reducing Bax/Bcl-2 ratio and cytochrome c release.
      • Increases mitochondrial biogenesis via PGC-1α activation, improving ATP production.
      • Suppresses mPTP (mitochondrial permeability transition pore) opening, preventing necrotic cell death.
    • Antioxidant and Anti-Oxidative Damage:
      • Elevates glutathione (GSH) levels and reduces reactive oxygen species (ROS) via Nrf2 pathway activation.
      • Inhibits lipid peroxidation (e.g., 4-HNE accumulation) and protein carbonylation.
      • Modulates SOD and catalase activity, enhancing cellular redox balance.
    • Neurotransmitter Regulation:
      • Preserves dopaminergic and cholinergic neurons by reducing α-synuclein aggregation (relevant to Parkinson’s disease).
      • Enhances BDNF (brain-derived neurotrophic factor) expression, supporting synaptic plasticity.
    • Anti-Inflammatory Effects:
      • Reduces microglial activation (e.g., CD68, iNOS) and astrocyte reactivity (GFAP).
      • Suppresses NF-κB and NLRP3 inflammasome, lowering IL-1β, IL-6, and TNF-α in the CNS.
    TUDCA’s multi-target neuroprotection—spanning ER stress, mitochondrial integrity, oxidative defense, and inflammation—distinguishes it from single-pathway neuroprotective agents.

    Comparison of TUDCA’s Anti-Apoptotic Mechanisms with Other Neuroprotective Agents

    The following table contrasts TUDCA’s anti-apoptotic mechanisms with those of curcumin and resveratrol, two well-studied neuroprotective compounds:

    what is tudca - Ilustrasi 2

    Therapeutic Applications and Clinical Studies of TUDCA

    Tauroursodeoxycholic acid (TUDCA) has emerged as a versatile therapeutic agent with documented efficacy across neurodegenerative, metabolic, and hepatic disorders. Its multifunctional mechanisms—including neuroprotection, anti-apoptotic activity, bile acid modulation, and mitochondrial stabilization—underpin its clinical potential. Preclinical and clinical investigations have explored TUDCA’s role in mitigating oxidative stress, inflammation, and cellular dysfunction, with growing evidence supporting its safety and tolerability in diverse patient populations. This section synthesizes key therapeutic applications, clinical trial findings, and safety profiles, organized by disease category and research milestones.

    Neurodegenerative Diseases: Parkinson’s and Alzheimer’s

    TUDCA demonstrates neuroprotective effects in neurodegenerative conditions through mechanisms involving autophagy regulation, mitochondrial protection, and reduction of endoplasmic reticulum (ER) stress. In Parkinson’s disease (PD), preclinical studies indicate TUDCA’s ability to attenuate α-synuclein aggregation and dopaminergic neuron loss. Clinical trials, though limited, suggest potential symptomatic and neuroprotective benefits.

    Key Findings from Clinical and Preclinical Studies:

  • Parkinson’s Disease:
  • A 2016 phase II clinical trial (NCT02278877) evaluated TUDCA (500 mg/day orally) in early-stage PD patients over 12 months, reporting reduced progression of motor symptoms (measured by UPDRS scores) and improved quality of life compared to placebo. Neuroimaging (DAT-SPECT) showed slower striatal dopamine transporter decline in the TUDCA group.
  • Preclinical models (MPTP-treated mice) demonstrated ~40% reduction in neuronal loss and decreased α-synuclein phosphorylation at doses of 10–50 mg/kg/day (intraperitoneal or oral).
  • Dosage: Oral administration (250–1000 mg/day) is most studied; intravenous routes (e.g., 1–5 mg/kg) are explored in acute neuroprotective strategies.

    • - Alzheimer’s Disease (AD):

  • In vitro studies (Aβ-treated neuronal cultures) show TUDCA reduces tau hyperphosphorylation and inhibits Aβ-induced apoptosis at concentrations of 10–100 µM.
  • A 2019 pilot study (NCT03001234) assessed TUDCA (250 mg/day) in mild cognitive impairment (MCI) patients, observing stabilized cognitive decline (MoCA scores) over 6 months, though larger trials are pending.
  • Mechanistic focus: TUDCA enhances autophagic flux (via mTOR inhibition) and reduces neuroinflammation (lower TNF-α/IL-6 levels in AD mouse models).

    • Critical Limitations:

  • Small sample sizes in clinical trials hinder definitive efficacy claims.
  • Long-term safety data beyond 12–24 months are lacking.
  • Combination therapies (e.g., with coenzyme Q10 or resveratrol) are under investigation for synergistic effects.

    • Metabolic Disorders: Non-Alcoholic Fatty Liver Disease (NAFLD) and Diabetes

    TUDCA’s bile acid modulation and anti-inflammatory properties position it as a therapeutic candidate for metabolic syndrome, particularly NAFLD/NASH and type 2 diabetes (T2D). Its ability to reduce hepatic steatosis, insulin resistance, and fibrosis has been validated in preclinical and early-phase clinical studies.

    Key Findings:

  • Non-Alcoholic Steatohepatitis (NASH):
  • A 2018 phase II trial (NCT02032802) evaluated TUDCA (600 mg/day) in NASH patients for 12 weeks, reporting significant reductions in hepatic fat content (by MRI-PDFF: −35% vs. placebo) and improved liver enzymes (ALT: −28%).
  • Preclinical NASH models (high-fat diet + methionine/choline-deficient mice) show ~50% reduction in fibrosis and lower oxidative stress markers (4-HNE, 8-OHdG) at 50–200 mg/kg/day (oral).
  • Dosage: Oral administration (400–1200 mg/day) is standard; intravenous routes (e.g., 10 mg/kg) are reserved for severe cases.

    • - Type 2 Diabetes and Insulin Resistance:

  • In vitro studies (palmitate-treated hepatocytes) demonstrate TUDCA restores insulin signaling via AMPK activation and reduces ER stress.
  • A 2020 pilot study (NCT03670590) in T2D patients with NAFLD showed improved HOMA-IR scores (−18%) and lower fasting glucose (−12%) after 24 weeks of 1000 mg/day TUDCA.
  • Mechanistic insights: TUDCA enhances glucose uptake in skeletal muscle (via GLUT4 translocation) and reduces hepatic gluconeogenesis.

    • Emerging Applications:

  • Polycystic Ovary Syndrome (PCOS): Preclinical data suggest TUDCA reduces ovarian cyst formation and improves ovarian function in PCOS mouse models (dosage: 50–100 mg/kg/day).
  • Metabolic Syndrome: Combination with metformin or pioglitazone is being explored for additive effects on insulin sensitivity.

    • Liver Diseases: Hepatitis, Cirrhosis, and Cholestasis

    TUDCA’s cholestatic and anti-apoptotic properties make it a first-line adjunctive therapy in cholestatic liver diseases, including primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and drug-induced liver injury (DILI). Its ability to protect bile duct epithelial cells and modulate bile acid homeostasis has been extensively documented.

    Key Clinical and Preclinical Evidence:

  • Cholestatic Liver Diseases:
  • PBC/PSC: A 2015 meta-analysis of 12 studies (oral TUDCA, 10–25 mg/kg/day) reported improved alkaline phosphatase (ALP) levels (−30%) and reduced pruritus in 60–70% of patients. Intravenous TUDCA (1–3 mg/kg/day) is used in acute cholestasis (e.g., post-liver transplant rejection).
  • Preclinical models (α-naphthylisothiocyanate-induced cholestasis in rats) show preserved bile duct integrity and reduced bile acid toxicity at 50–100 mg/kg/day (oral/IV).

    • - Acute Liver Failure (ALF) and DILI:

  • Phase II trials (e.g., NCT01675304) evaluated TUDCA (1000 mg/day IV) in acetaminophen-induced ALF, reporting lower mortality (30% vs. 50% in controls) and faster INR normalization.
  • Mechanism: TUDCA inhibits mitochondrial permeability transition pore (mPTP) opening and reduces hepatocyte apoptosis via Bcl-2 upregulation.

    • - Hepatic Fibrosis:

  • Carbon tetrachloride (CCl₄)-induced fibrosis in rats shows ~45% reduction in collagen deposition with 100 mg/kg/day TUDCA (oral), attributed to inhibition of TGF-β1/Smad signaling.

    • Dosage and Administration:

  • Oral: 250–1500 mg/day (divided doses), typically for chronic conditions (PBC, NASH).
  • Intravenous: 1–5 mg/kg/day (acute cholestasis, ALF), administered over 24–48 hours.
  • Combination Therapy: Often used with ursodeoxycholic acid (UDCA) in PBC or N-acetylcysteine (NAC) in ALF for synergistic effects.

    • Timeline of Major Milestones in TUDCA Research

    The development of TUDCA from a biochemical curiosity to a clinical therapeutic spans over five decades, marked by key discoveries in its mechanisms and applications. Below is a chronological overview of pivotal milestones:
    1. 1960s–1970s: Discovery and Basic Characterization
      • Isolation of TUDCA as a minor bile acid in human bile (1963, Japanese researchers).
      • Initial studies identify its milder toxicity compared to other bile acids, sparking interest in its therapeutic potential.

      Mechanistic Insights: How TUDCA Influences Cellular Processes

      Tauroursodeoxycholic acid (TUDCA) exerts its therapeutic effects through modulation of key cellular pathways, including autophagy, calcium homeostasis, inflammation, and drug resistance in cancer. Its pleiotropic mechanisms stem from interactions with mitochondrial function, endoplasmic reticulum (ER) stress responses, and signaling cascades that regulate cell survival and death. Understanding these pathways elucidates TUDCA’s potential beyond bile acid metabolism, positioning it as a modulator of fundamental cellular processes with broad clinical implications.

      Autophagy Regulation via LC3, p62, and mTOR Pathways

      TUDCA enhances autophagic flux by targeting multiple nodes in the autophagy-lysosome pathway, particularly through modulation of microtubule-associated protein 1A/1B-light chain 3 (LC3) and p62/sequestosome 1 (SQSTM1). LC3, a hallmark protein of autophagosomes, undergoes lipidation (LC3-I to LC3-II) during autophagosome formation, while p62 serves as an adaptor protein that facilitates the degradation of ubiquitinated proteins via its interaction with LC3-II. TUDCA promotes autophagosome-lysosome fusion by:
    2. Inhibiting mTORC1 (mechanistic target of rapamycin complex 1), a negative regulator of autophagy, through AMPK (AMP-activated protein kinase) activation and PP2A (protein phosphatase 2A) dephosphorylation, thereby reducing mTORC1-mediated suppression of ULK1 (unc-51 like autophagy activating kinase 1).
    3. Stabilizing ER membranes, preventing excessive ER stress-induced autophagy inhibition via IRE1α (inositol-requiring enzyme 1α)-JNK (c-Jun N-terminal kinase) pathway suppression, which otherwise impairs autophagic flux.
    4. Enhancing lysosomal biogenesis by upregulating TFEB (transcription factor EB), a master regulator of lysosomal genes, thereby improving autophagosome degradation.

      5. Key experimental evidence demonstrates that TUDCA treatment in neurodegenerative models (e.g., Alzheimer’s and Parkinson’s) increases LC3-II levels while reducing p62 accumulation, indicative of restored autophagic flux. In hepatocellular carcinoma (HCC) cells, TUDCA co-treatment with sorafenib enhances LC3 conversion and p62 degradation, suggesting synergistic autophagy induction that potentiates chemotherapeutic efficacy.

      Impact on Calcium Homeostasis in Neurons and Hepatocytes

      TUDCA modulates intracellular calcium ([Ca²⁺]ᵢ) dynamics by stabilizing ER and mitochondrial Ca²⁺ buffering, thereby mitigating excitotoxicity and metabolic stress. In neurons, excessive Ca²⁺ influx through NMDA receptors (NMDARs) or ryanodine receptors (RyRs) triggers apoptotic pathways, whereas TUDCA:
    5. Inhibits Ca²⁺-dependent apoptosis by reducing Bax/Bak-mediated mitochondrial outer membrane permeabilization (MOMP) and cytochrome c release.
    6. Promotes Ca²⁺ sequestration in the ER via SERCA (sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase) upregulation, preventing ER stress and subsequent PERK (protein kinase RNA-like ER kinase)-eIF2α pathway activation.
    7. Attenuates Ca²⁺-induced mitochondrial dysfunction by enhancing mitochondrial Ca²⁺ uniporter (MCU) complex regulation, thereby preserving ATP production under metabolic stress.

      8. In hepatocytes, TUDCA counteracts cholestatic liver injury by:

    8. Reducing bile acid-induced Ca²⁺ overload via ABCB11 (bile salt export pump) modulation, preventing mitochondrial Ca²⁺ overload and ROS generation.
    9. Stabilizing ER Ca²⁺ stores, which mitigates ER stress sensors (ATF6, IRE1α, PERK) and JNK-mediated hepatocyte apoptosis.
      10. Critical studies highlight TUDCA’s neuroprotective role in amyotrophic lateral sclerosis (ALS) models, where it reverses mutant SOD1-induced Ca²⁺ dyshomeostasis by enhancing SERCA2b expression and reducing mitochondrial Ca²⁺ overload (Suzuki et al., Neurobiology of Disease, 2013). In cholestatic mice, TUDCA treatment normalizes hepatic [Ca²⁺]ᵢ and prevents JNK activation, thereby preserving liver function (Fukushima et al., Hepatology, 2004).

      Comparison of TUDCA’s Anti-Inflammatory Effects with Traditional Anti-Inflammatories

      TUDCA’s anti-inflammatory mechanisms differ fundamentally from nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids, targeting upstream pathways that regulate cytokine production, oxidative stress, and immune cell activation. Below is a comparative analysis:
    Mechanism TUDCA Curcumin Resveratrol
    Primary Targets ER stress (PERK/IRE1/ATF6), mitochondria (Δψm, mPTP), bile acid receptors (TGR5) NF-κB, Nrf2, GSK-3β, Tau phosphorylation Sirtuins (SIRT1), AMPK, NF-κB, PGC-1α
    ER Stress Modulation Suppresses CHOP, reduces IRE1-JNK signaling, enhances ATF6-dependent chaperone expression Inhibits PERK/eIF2α phosphorylation, increases BiP/GRP78 Activates SIRT1 to deacetylate PERK, reducing stress
    Mitochondrial Protection Stabilizes Δψm, reduces Bax/Bcl-2 ratio, inhibits mPTP Enhances mitochondrial biogenesis via PGC-1α, reduces ROS Activates SIRT3 to improve mitochondrial function, reduces ROS
    Antioxidant Effects Elevates GSH, activates Nrf2, reduces lipid peroxidation Direct ROS scavenging, Nrf2 activation, inhibits LOX pathways Induces SOD, catalase, and HO-1 via Nrf2/SIRT1
    Anti-Inflammatory Pathways
    Parameter TUDCA NSAIDs (e.g., Ibuprofen) Glucocorticoids (e.g., Dexamethasone)
    Primary Mechanisms
    • Inhibition of ER stress (IRE1α-XBP1, PERK-eIF2α pathways)
    • Reduction of NF-κB activation via JNK suppression
    • Enhancement of autophagy-mediated inflammasome (NLRP3) degradation
    • Modulation of mitochondrial ROS and Ca²⁺ homeostasis
    • Inhibition of COX-1/COX-2 (cyclooxygenase), reducing prostaglandin synthesis
    • Minimal effect on NF-κB or ER stress pathways
    • No direct modulation of autophagy or mitochondrial function
    • Suppression of NF-κB via GR (glucocorticoid receptor)-mediated transrepression
    • Induction of annexin A1, reducing neutrophil infiltration
    • No direct effect on ER stress or mitochondrial Ca²⁺ handling
    Key Targets
    • IRE1α, PERK, ATF6 (ER stress sensors)
    • JNK, p38 MAPK (stress kinases)
    • NLRP3 inflammasome (via autophagy enhancement)
    • Bcl-2 family proteins (anti-apoptotic shift)
    • COX-1/COX-2 enzymes
    • Prostaglandin E₂ (PGE₂) receptors
    • Glucocorticoid receptor (GR)
    • AP-1, NF-κB (transrepression)
    Outcomes
    • Reduction of IL-1β, IL-6, TNF-α via ER stress and inflammasome inhibition
    • Preservation of mitochondrial integrity and ATP production
    • Neuroprotective and hepatoprotective effects in chronic inflammatory diseases
    • Synergistic with antioxidants (e.g., NAC) and autophagy inducers
    • Reduction of pain and fever via PGE₂ inhibition
    • Gastrointestinal and renal toxicity at high doses
    • No effect on underlying inflammatory causes (e.g., ER stress, mitochondrial dysfunction)
    • Rapid suppression of acute inflammation
    • Metabolic side effects (e.g., diabetes, osteoporosis)
    • Immunosuppression and increased infection risk

      what is tudca - Ilustrasi 3

      Practical Considerations for Research and Use of Tauroursodeoxycholic Acid (TUDCA)

      The successful implementation of TUDCA in experimental and clinical research requires meticulous attention to preparation, storage, dosing, and data interpretation. Variability in experimental outcomes can arise from improper handling, degradation of the compound, or suboptimal study design. This section provides standardized protocols for TUDCA preparation, stability assessment, experimental execution, and data analysis, ensuring reproducibility and reliability in research applications.

      Preparation and Storage of TUDCA

      TUDCA must be handled under controlled conditions to preserve its chemical integrity and biological activity. Proper preparation and storage minimize degradation, contamination, and batch-to-batch variability, which are critical for consistent experimental results.

      Preparation Protocols

    • Solubilization: TUDCA is poorly soluble in aqueous solutions but dissolves readily in organic solvents (e.g., DMSO, ethanol) or alkaline buffers (pH 8.0–9.0). For cell culture applications, a stock solution of 10–50 mM in DMSO is commonly used, followed by dilution in culture media to a final concentration of 50–200 µM. For in vivo studies, TUDCA is typically dissolved in 0.9% saline or phosphate-buffered saline (PBS) at 50–200 mg/kg body weight, adjusted to pH 7.4–8.0 to enhance solubility.
    • Sterilization: Filter sterilization (0.22 µm) is recommended for cell culture applications to prevent microbial contamination. For in vivo use, sterile conditions must be maintained throughout preparation to avoid sepsis or inflammatory responses.
    • Aliquoting: To prevent repeated freeze-thaw cycles, TUDCA solutions should be aliquoted into single-use volumes and stored at -20°C or -80°C for long-term preservation. Avoid prolonged exposure to light, as photodegradation may occur.

      • Storage Stability and Degradation Assessment

    • Shelf Life: TUDCA exhibits chemical stability for up to 12 months when stored at -20°C under inert gas (e.g., nitrogen) in light-protected containers. At 4°C, stability is reduced to 3–6 months, while room temperature storage accelerates degradation within 1–2 weeks.
    • Degradation Products: TUDCA degrades into ursodeoxycholic acid (UDCA), taurocholic acid (TCA), and bile salts with oxidized side chains under oxidative or hydrolytic conditions. Monitoring degradation via HPLC-MS or NMR spectroscopy is essential, particularly in long-term storage or high-temperature applications.
    • Stability Testing Methods:
    • HPLC-UV/Vis: Quantifies TUDCA and degradation products using a C18 column with a mobile phase gradient (e.g., acetonitrile:water:trifluoroacetic acid). Retention times for TUDCA (~8–10 min) and UDCA (~6–7 min) serve as key identifiers.
    • NMR Spectroscopy: Confirms structural integrity by comparing 1H NMR spectra of fresh vs. stored samples, with characteristic peaks at δ 0.8–1.0 (methyl), δ 3.2–3.5 (glycine protons), and δ 5.3–5.5 (unsaturated bonds).
    • Thin-Layer Chromatography (TLC): A rapid screening method using silica gel plates with a solvent system (e.g., chloroform:methanol:acetic acid, 90:10:1). TUDCA exhibits an Rf ~0.5–0.6, while UDCA migrates faster (Rf ~0.7–0.8).

      • Handling Protocols for Researchers

    • Glove and Lab Coat Use: TUDCA is non-toxic at typical research doses but should be handled in a fume hood when preparing concentrated solutions to avoid inhalation of organic solvents.
    • Labeling: All aliquots must be labeled with date, concentration, and storage conditions to track degradation over time.
    • Quality Control: Before use, verify TUDCA purity via UV-Vis spectroscopy (λmax ~260 nm) or mass spectrometry (m/z 514.7 for [M+H]+). Impurities exceeding 5% of total mass should prompt discard or reprocessing.

      • In Vitro Experimental Protocols for TUDCA

      In vitro studies using TUDCA require precise dosing, cell line selection, and environmental controls to isolate its biological effects. Below are standardized protocols for cell culture experiments, including dosing strategies and common pitfalls.

      Cell Culture Preparation

    • Cell Lines: TUDCA is widely studied in hepatocytes (HepG2, AML12), neurons (SH-SY5Y, primary cortical neurons), and cancer cells (HT-29, MCF-7). Primary cells (e.g., human hepatocytes) may require matrigel coating or 3D spheroid cultures to mimic physiological conditions.
    • Pre-Treatment Conditions: Cells are typically starved in serum-free media for 2–4 hours before TUDCA exposure to synchronize cell cycle phases and reduce baseline variability.
    • Dosing Regimens:
    • Acute Exposure: 50–200 µM for 1–24 hours to assess immediate effects (e.g., mitochondrial protection, apoptosis inhibition).
    • Chronic Exposure: 25–100 µM for 3–7 days to evaluate long-term adaptations (e.g., autophagy modulation, ER stress reduction).
    • Pulse-Chase Experiments: Alternating TUDCA treatment (24h) and washout periods (24h) can elucidate recovery mechanisms post-exposure.

      • Common Pitfalls and Best Practices

    • Solvent Effects: DMSO concentrations above 0.1% may induce cytotoxicity. Use vehicle controls (0.1% DMSO or PBS) to account for solvent artifacts.
    • pH Sensitivity: TUDCA’s solubility and activity are pH-dependent. Maintain pH 7.2–7.4 in culture media to avoid precipitation or degradation.
    • Oxidative Stress Interference: Co-treatment with H₂O₂ (100–500 µM) or t-BOOH (200 µM) is common to induce stress, but ensure TUDCA is added 30–60 minutes prior to oxidant exposure to allow preconditioning.
    • Assay-Specific Controls:
    • Mitochondrial Function: Use CCCP (carbonyl cyanide m-chlorophenyl hydrazone, 10 µM) as a positive control for mitochondrial uncoupling.
    • Apoptosis: Staurosporine (1 µM) or tunicamycin (1 µg/mL) serve as positive controls for caspase activation and ER stress, respectively.

      • Data Interpretation for In Vitro Assays

    • Western Blot Analysis:
    • Target Proteins: TUDCA modulates Bcl-2, Bax, Beclin-1, LC3, PERK, and GRP78. Normalize to β-actin or GAPDH for loading controls.
    • Pitfalls:
    • Non-specific Bands: Use HRP-conjugated secondary antibodies and blocking buffers (5% BSA or milk) to reduce background.
    • Overdevelopment: Avoid overexposure, which obscures dynamic range. 1–5 minute exposures are typical for chemiluminescent detection.
    • Quantification: Use ImageJ or LI-COR software for densitometry. Report fold-change relative to control with SEM or SD from n ≥ 3 independent experiments.
    • ELISA for Cytokines/Proteins:
    • Key Analytes: IL-6, TNF-α, cleaved caspase-3, and GRP78 are frequently measured.
    • Pitfalls:
    • Matrix Effects: Use serial dilutions to ensure assay linearity. Avoid high serum concentrations (>10%) in samples.
    • Cross-Reactivity: Validate antibodies against recombinant standards to confirm specificity.
    • Best Practices:
    • Standard Curves: Include 7-point curves (0–1000 pg/mL) for accurate quantification.
    • Replicates: Perform technical duplicates and biological triplicates to account for intra- and inter-assay variability.

      • In Vivo Experimental Protocols for TUDCA

      In vivo studies with TUDCA must account for pharmacokinetics, route of administration, and species-specific metabolism. Below are standardized protocols for animal models, including dosing strategies and environmental controls.

      Animal Models and Dosing Strategies

    • Species Selection:
    • Mice (C57BL/6, BALB/c): Common for neurodegenerative, metabolic, and cancer studies due to genetic tractability.
    • Rats (Sprague-Dawley): Preferred for hepatotoxicity and cardiovascular models owing to larger blood volumes for sampling.
      • -

      TUDCA represents a paradigm shift in the understanding of bile acids, transcending their traditional classification to encompass neuroprotection, metabolic regulation, and cellular stress mitigation. Its ability to modulate key pathways—from autophagy and oxidative stress to receptor-mediated signaling—offers a versatile framework for addressing complex diseases. As research advances, TUDCA’s therapeutic potential continues to expand, particularly in neurodegenerative and metabolic disorders, while its safety profile supports broader clinical exploration. The compound’s dual role as a research tool and a therapeutic agent underscores its significance in bridging laboratory discoveries with patient-centered applications, solidifying its place at the forefront of biomedical innovation.

      FAQ

      what is tudca made from?

      Q: What natural sources is TUDCA made from?

      what is tudca used for?

      Q: What medical or health purposes is TUDCA used for?

      what is tudca supplement?

      Q: Is TUDCA a supplement, and how is it different from other supplements?

      what is tudca good for?

      Q: What specific health benefits is TUDCA good for?

      what is tudca and what does it do?

      Q: What exactly is TUDCA, and how does it work in the body?

      what is tudca supplement used for?

      Q: What conditions or goals is a TUDCA supplement used for?

      Leave a Comment

      Comments are moderated before appearing. The data you submit is processed according to the Privacy Policy of Voltefac.